Merck and Biomet link up to target European biomaterial orthopaedic market
This article was originally published in Clinica
Executive Summary
Merck KGaA and Biomet are to form a 50:50 joint venture to market biomaterial orthopaedic products in Europe. The new company will operate under the name Biomet-Merck and is expected to have pro forma turnover of more than $200 million next year.